Robust clinical trial data underscore progress in oncology. Roche’s Phase 3 Sunmo trial shows that combining bispecific antibody Lunsumio with ADC Polivy substantially outperforms standard chemo for large B-cell lymphoma patients, reducing progression risk by 59%. Exelixis’ oral kinase inhibitor zanzalintinib demonstrated superiority over Bayer’s Stivarga in colorectal cancer, significantly improving overall survival, propelling it toward a potential $5 billion product. These successes highlight expanding immuno-oncology and targeted therapy roles in difficult cancers, with regulatory submissions anticipated.